Grants Archive - Page 178 of 180 - Kenneth Rainin Foundation

Gut inflammation alters the bacterial communities in the gut (the microbiome), and these disruptions are thought to make inflammation even worse. Understanding and derailing this cycle could provide new avenues for IBD therapy. Although we know that inflammation can change “who’s there” in the gut microbiome, this project will determine whether harder-to-measure changes within the […]

We have discovered a novel single-gene defect in patients with pediatric IBD, setting the stage for new molecular and cellular discoveries to dissect biology stemming from human disease. Here, we will pursue two aims that will open new doors by leveraging the strength of preclinical models to uncover mechanisms by which the gene we identified […]

Inflammatory Bowel Diseases (IBDs) are typified by bouts of inflammation-induced epithelial damage and repair. By take cues from their microenvironment or “niche”, intestinal stem cells (ISCs) direct these fluctuating pathological and reparative states in IBD. Yet, we do not understand which cells comprise the inflamed ISC niche and how they switch on programs of repair. […]

Accumulating data supports the concept that IBD has a preclinical period that may be amenable to early diagnosis and intervention. Understanding the molecular underpinnings of this preclinical period in disease pathogenesis offers new opportunities in risk prediction and prevention. We have recently reported the first data from a large study using longitudinal pre-diagnostic samples from […]

Crohn’s disease is a chronic inflammatory disease of the intestinal tract. It has been increasingly appreciated that two factors are involved beyond the genetic setup of individuals: 1.) Intestinal microbial dysbiosis and 2.) immune system dysregulation. Intestinal microbial dysbiosis refers to changes in the billions of bacteria that are growing in our gut. In healthy […]

It is now well recognized that IBD develops as a result of complex gene-environment interactions. Since there is no cure for IBD, treatment has focused on alleviating the symptoms. A better understanding of the fundamental mechanisms that drive the development and progression of IBD would allow for the design of more specific and effective treatments. […]

In IBD, the microbes within the intestinal tract, collectively known as the microbiota, are targeted by inappropriate immune responses. There are also a number of changes in the microbiota composition that are thought to drive or amplify IBD pathology. One of these is the expansion of E. coli. However, our preliminary data has identified select […]

Our project aims to revolutionise the role of the microbiome to develop therapies for IBD in the near future. Recent trials of fecal transplant in UC have shown the potential that changing the gut’s microbes can have in IBD care. We will advance this technology for all IBD patients. Our group has developed new methods […]

Abdominal pain, discomfort, and cramping are symptoms commonly experienced by individuals who suffer from inflammatory bowel disease or inflammatory bowel syndrome. Our conscious perception of gastrointestinal pain begins when sensory nerve fibers in the gut are activated or sensitized by chemical agents that we ingest, or that are produced by inflammation, stress, or bacteria. While […]